0001062993-23-007574.txt : 20230323 0001062993-23-007574.hdr.sgml : 20230323 20230323193137 ACCESSION NUMBER: 0001062993-23-007574 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230321 FILED AS OF DATE: 20230323 DATE AS OF CHANGE: 20230323 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Borges Luis CENTRAL INDEX KEY: 0001684015 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40498 FILM NUMBER: 23757443 MAIL ADDRESS: STREET 1: TWO CORPORATE DRIVE STREET 2: C/O FIVE PRIME THERAPEUTICS, INC. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Century Therapeutics, Inc. CENTRAL INDEX KEY: 0001850119 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 842040295 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 215-981-4000 MAIL ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0407 4 2023-03-21 0001850119 Century Therapeutics, Inc. IPSC 0001684015 Borges Luis 3675 MARKET STREET PHILADELPHIA PA 19104 0 1 0 0 Chief Scientific Officer 0 Common Stock 2023-03-21 4 M 0 63616 1.03 A 107366 D Common Stock 2023-03-21 4 S 0 63616 3.7706 D 43750 D Common Stock 2023-03-22 4 M 0 65698 1.03 A 109448 D Common Stock 2023-03-22 4 S 0 65698 3.7237 D 43750 D Common Stock 2023-03-23 4 M 0 220930 1.03 A 264680 D Common Stock 2023-03-23 4 S 0 15597 3.55 D 249083 D Stock Option (right to buy) 1.03 2023-03-21 4 M 0 63616 0 D 2029-07-17 Common Stock 63616 294080 D Stock Option (right to buy) 1.03 2023-03-22 4 M 0 65698 0 D 2029-07-17 Common Stock 65698 228382 D Stock Option (right to buy) 1.03 2023-03-23 4 M 0 220930 0 D 2029-07-17 Common Stock 220930 7452 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.75 to $3.935, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.57 to $3.79, inclusive. The option vests 25% on April 1, 2020, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. /s/ Michael Diem, Attorney-in-Fact 2023-03-23